Merck, 69390-4, Bacteriophage CE6 - Novagen

General description
λ phage for delivery of T7 RNA polymerase
Bacteriophage CE6 is a recombinant lambda phage containing the T7 RNA polymerase gene (Studier 1986). The polymerase gene is cloned into the int gene, such that it is transcribed from the pL and pI promoters of the phage during infection. λCE6 can be used to provide a source of T7 RNA polymerase to susceptible host cells carrying T7 expression plasmids. In general, it is used when a target gene is so toxic that the plasmid cannot be maintained in DE3 lysogenic hosts, or with alternative hosts that are not DE3 lysogens. The phage has λcI857 immunity and the Sam7 mutation, which requires supF hosts for lytic growth (neither lytic growth nor different immunity are required for T7 RNA polymerase synthesis). It is provided as a high titer lysate and includes host strains LE392 (rK₁₂ mK₁₂⁺) and ED8739 (rK₁₂ mK₁₂) as glycerol stocks. The 10-ml size is enough to induce up to 100 ml culture.
This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
Other Notes
•0.2 or 10 mlCE6 Lysate

•0.2 mlLE392 glycerol stock

•0.2 mlED8739 glycerol stock

Studier, F.W. and Moffatt, B.A. 1986 J. Mol. Biol. 189, 113.
Legal Information
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Multiple Toxicity Values, refer to MSDS (O)